Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: An integrated approach

Cardiology Clinics

Volumn 23, Issue 2, 2005, Pages 193-210

  Srikanth, Sundararajan ^a   Deedwania, Prakash ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLONIDINE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; METFORMIN; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; TICLOPIDINE; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; METABOLIC SYNDROME X; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; RETINOPATHY; REVIEW; STROKE;

EID: 13444292192     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2004.11.002     Document Type: Review

References (54)

1. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
2. Centers for Disease Control. National Health and Nutrition Examination Survey 1999-2000 data files. Available at: http://www.cdc.gov/nchs/about/major/ nhanes/NHANES99_00.htm. Accessed December 21, 2004.
3. International Diabetes Federation IGT/IFG Consensus. Statement Report of an expert consensus workshop, August 1-4, 2001. Stoke Poges, United Kingdom. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention Diabet Med 19 2002 708 723
4. S.H. Saydah, M.S. Eberhardt, and C.M. Loria Age and the burden of death attributable to diabetes in the United States Am J Epidemiol 156 2002 714 719
5. K. Gu, C.C. Cowie, and M.I. Harris Diabetes and decline in heart disease mortality in US adults JAMA 281 1999 1291 1297
6. J.B. Ruige, W.J. Assendelft, and J.M. Dekker Insulin and risk of CV disease: a meta-analysis Circulation 97 10 1998 996 1001
7. J. Yip, F.S. Facchini, and G.M. Reaven Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease J Clin Endocrinol Metab 83 1998 2773 2776
8. F.S. Facchini, N. Hua, and F. Abbasi Insulin resistance as a predictor of age related diseases J Clin Endocrinol Metab 86 2001 3574 3578
9. T.C. Fagan, and P.C. Deedwania The cardiovascular dysmetabolic syndrome Am J Med 105 1A 1998 77S 82S
10. F. Abbasi, T. McLaughlin, and C. Lamendola The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers J Clin Endocrinol Metab 85 2000 1252 1254
11. M.R. Taskinen, and U. Smith Lipid disorders in NIDDM: implications for treatment J Intern Med 244 1998 361 370
12. A. Garg Treatment of diabetic dyslipidemia Am J Cardiol 81 1998 47B 51B
13. M.M. Veniant, M.A. Sullivan, and S.K. Kim Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100 J Clin Invest 106 2000 1501 1510
14. J. Stamler, I. Vaccaro, and J.D. Neaton Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
15. R.C. Turner, H. Millns, and H.A. Neil Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 1998 823 828
16. A. Garg, and S.M. Grundy Management of dyslipidemia in NIDDM Diabetes Care 13 1990 153 169
17. K. Pyorola, T.R. Pederson, and J. Kjekshus Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 20 1997 614 620
18. R.B. Goldberg, M.J. Mellies, and F.M. Sacks for the CARE investigators Cardiovascular events and their reduction with pravastatin in diabetic and glucose- intolerant myocardial infarction survivors with average cholesterol and recurrent events (CARE) trial Circulation 98 1998 2513 2519
19. R. Collins, J. Armitage, S. Parish Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 9374 2003 2005 2016
20. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington for the CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial Lancet 364 9435 2004 685 696
21. H.B. Rubins, S.J. Robins, and D. Collins for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol N Engl J Med 341 1999 410 418
22. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
23. S.M. Grundy, J.I. Cleeman, and C.N. Bairey Merz for the Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
24. E. Ferrannini, G. Buzzigoli, and R. Bonadona Insulin resistance in essential hypertension N Engl J Med 317 1987 350 357
25. A.L.M. Swislocki, B.B. Hoffman, and G.M. Raven Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension Am J Hypertens 2 1989 419 423
26. United Kingdom Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications of type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
27. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial Lancet 351 1998 1755 1762
28. J.T. Wright Jr., D.W. Jones, and L.A. Green The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2571
29. G.L. Bakris, M. Williams, and L. Dworkin Preserving renal function in adults with hypertension and diabetes: a consensus approach Am J Kidney Dis 36 3 2000 646 661
30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy Lancet 355 2000 253 259 [published correction appears in Lancet 2000;356:850]
31. Kidney Disease Outcome Quality Initiative K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl 1 2002 S1 S266
32. N. Poulter, and B. Williams Doxazosin for the management of hypertension: implications of the findings of the ALLHAT Trial Am J Hypertens 14 2001 1170 1172
33. United Kingdom Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
34. United Kingdom Prospective Diabetes Study Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
35. K.T. Khaw, N. Wareham, and R. Luben Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk) BMJ 322 7277 2001 15 18
36. European Diabetes Epidemiology (DECODE) Group Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26 3 2003 688 696
37. Collaborative Group of the Primary Prevention Project Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice Lancet 357 2002 89 95
38. J.A. Colwell Aspirin therapy in diabetes Diabetes Care 26 Suppl 1 2003 S87 S88
39. United States Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: recommendations and rationale Ann Intern Med 136 2001 157 160
40. Antithrombotic Trialists' Collaboration Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
41. D. Bhatt, S. Marso, A. Hirsh, and P. Ringleb Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 2002 625 628
42. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
43. T.J. Hoerger, A.D. Bethke, and A. Richter The CDC Diabetes Cost-Effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes JAMA 287 2002 2542 2551
44. S. Saydah, J. Fradkin, and C. Cowie Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 291 2004 335 342
45. C.M. Clark, J.E. Fradkin, and R.G. Hiss The National Diabetes Education Program, changing the way diabetes is treated Diabetes Care 24 2001 617 618
46. B.B. Fleming, S. Greenfield, and M.M. Engelgau The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic Diabetes Care 24 2001 1815 1820
47. American Diabetes Association Standards of Medical Care in Diabetes - position statements Diabetes Care 27 2004 S15 S35
48. J. Lindstrom, J.G. Eriksson, and T.T. Valle Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study: results from a randomized clinical trial J Am Soc Nephrol 14 7 Suppl 2 2003 S108 S113
49. The DPP Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
50. J.L. Chiasson, R.G. Josse, and R. Gomis for the STOP-NIDDM Trial Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 359 2002 2072 2077
51. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The seventh report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) JAMA 289 19 2003 2560 2572
52. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report published by the National Institutes of Health, National Heart, Lung, and Blood Institute in June 1998.
53. R.P. Lauber, and N.F. Sheard The American Heart Association dietary guidelines for 2000: a summary report Nutr Rev 59 9 2001 298 306
54. B.E. Sobel, and D.J. Schneider Platelet function, coagulopathy and impaired fibrinolysis in diabetes Cardiol Clin 22 4 2004 511 526